Toward Imaging of the GABA Transporter Type 1 In Vivo: Quantitative Evaluation of 4 Novel PET Radiotracers in Nonhuman Primates
Journal of Nuclear Medicine · 2025
DOI: 10.2967/jnumed.125.270332 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Paul Gravel und 14 weiteren Autor:innen. Beteiligte Einrichtung: PET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, Connecticut; paul.gravel@yale.edu. Hauptthemen laut MEDLINE: Positron-Emission Tomography, GABA Plasma Membrane Transport Proteins, Radiopharmaceuticals. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS, NCRR NIH HHS.
Abstract (Originalsprache)
The main inhibitory neurotransmitter in the central nervous system is γ-aminobutyric acid (GABA). GABA transporter type 1 (GAT-1) is the principal GABA transporter in the brain, and it plays a crucial role in modulating GABA signaling. Its potential role in several neuropsychiatric disorders makes it an important target to study. Although PET radiotracers exist for the GABA receptors, none have been successful for imaging GAT-1. The focus of this work was to evaluate the kinetic behavior of 4 novel 18F-labeled PET radiotracers (18F-GATT-31, 18F-GATT-34, 18F-GATT-39, and 18F-GATT-44) for imaging GAT-1 in nonhuman primates and to select the best radiotracer to progress to human studies.
Methods
Twenty scans were acquired from 4 rhesus monkeys (Macaca mulatta). Each monkey received 0.5 mg/kg of tiagabine given approximately 20 min before radiotracer injection and underwent baseline and blocking scans with 18F-GATT-31, 18F-GATT-34, 18F-GATT-39, or 18F-GATT-44 on a small-animal PET scanner. During each scan, arterial blood was collected for measurement of the input function. Kinetic analysis was performed using a 1-tissue compartment model, 2-tissue reversible model (k 4 > 0), and 2-tissue irreversible model (k 4 = 0), including a blood volume fraction term and a time-delay term.
Results
All radiotracers exhibited good, albeit slow, brain uptake within the cortical and subcortical gray matter regions and cerebellum. Peripheral metabolism was slow for 18F-GATT-34, 18F-GATT-39, and 18F-GATT-44, with greater than 75% remaining as the parent compound, but was somewhat faster for 18F-GATT-31 (63%) over the 3-h scans. The 1-tissue compartment model delivered a reliable performance on the basis of the overall lowest Akaike information criterion and an SE of less than 10% for the volume of distribution. 18F-GATT-39 and 18F-GATT-34 were eliminated from progressing to human studies because of low brain uptake or low specific binding. The 2 remaining radiotracers had similar characteristics, with 18F-GATT-44 showing slightly superior performance over 18F-GATT-31, with more consistent tiagabine blocking results (65%-71%) and with nondisplaceable binding potential (BPND) values ranging from 1.2 to 4.2 across gray matter structures.
Conclusion
We successfully developed 4 GAT-1 selective radiotracers and evaluated them in nonhuman primates with kinetic analysis and blocking studies with tiagabine. Of these compounds, 18F-GATT-44 exhibited consistent results and reasonable BPND values and will progress to human studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- PET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, Connecticut; paul.gravel@yale.edu.
- PET Center, Department of Radiology and Biomedical Imaging, Yale University, New Haven, Connecticut.
- Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland; and.
- Department of Psychiatry, Yale University, New Haven, Connecticut.
Förderung
- NIMH NIH HHS
- NCRR NIH HHS
Zitieren
APA
Gravel, P., Gu, J., Wang, C., Volpi, T., Gallezot, J. D., Holden, D., Fowles, K., Zheng, M. Q., Zhang, L., Borroni, E., Honer, M., Gobbi, L., Tamagnan, G., Huang, Y., & Carson, R. E. (2025). Toward Imaging of the GABA Transporter Type 1 In Vivo: Quantitative Evaluation of 4 Novel PET Radiotracers in Nonhuman Primates. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.270332
Vancouver
Gravel P, Gu J, Wang C, Volpi T, Gallezot JD, Holden D, et al. Toward Imaging of the GABA Transporter Type 1 In Vivo: Quantitative Evaluation of 4 Novel PET Radiotracers in Nonhuman Primates. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.125.270332
BibTeX
@article{Gravel2025,
author = {Gravel, Paul and Gu, Jiwei and Wang, Chao and Volpi, Tommaso and Gallezot, Jean-Dominique and Holden, Daniel and Fowles, Krista and Zheng, Ming-Qiang and Zhang, Li and Borroni, Edilio and Honer, Michael and Gobbi, Luca and Tamagnan, Gilles and Huang, Yiyun and Carson, Richard E},
title = {Toward Imaging of the GABA Transporter Type 1 In Vivo: Quantitative Evaluation of 4 Novel PET Radiotracers in Nonhuman Primates},
journal = {Journal of Nuclear Medicine},
year = {2025},
doi = {10.2967/jnumed.125.270332}
}
EUVIMED